<DOC>
	<DOCNO>NCT00215124</DOCNO>
	<brief_summary>The objective obtain initial information regard safety efficacy use Filgrastim set acute myocardial infarction . The secondary objective obtain information regard mobilization relevant stem cell progenitor cell Filgrastim set obtain clinical information may helpful assessment safety efficacy drug utilize . It one center , randomize , placebo control , dose escalation , blind study . It 2:1 randomization 9 patient total . Filgrastim 10 mcg/kg/day administer SQ 5 day vs. placebo . Primary endpoint death /or myocardial rupture change leave ventricular ejection fraction baseline 30 day . 9 pt . already complete first phase trial use Filgrastim 5 mcg/kg/day .</brief_summary>
	<brief_title>A Phase I - II Safety Study Filgrastim ( Neupogen ) Improve Left Ventricular Function After Severe Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Acute Myocardial Infarction within 6 hour symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>